Fred Hutchinson Cancer Research Center preclinical researchers seek to marry CRISPR and immunotherapy to try and improve treatment for leukemia. Why? For years, doctors have been plagued by a lose-lose trade-off: a bull’s-eye for certain cancer-killing drugs also...
Although similarities exist between childhood and adult leukemias, evidence suggests that the cancers don’t share the same genetic roots. New research hints that childhood leukemia may be able to hijack only young, developing cells—like those found in...
An experimental drug developed out of Norway gains momentum including FDA Fast Track, and its maker, BerGenBio ASA, selected drug development and contract drug manufacturer Piramal Pharma The investigational candidate, bemcentinib, was recently designated by the U.S....
St. Jude Children’s Research Hospital concluded the Total Therapy Study 16 evidencing the ability to successfully reduce the rate of central nervous system (CNS) relapse to 1.8% for acute lymphoblastic leukemia (ALL) in children. The Problem: ALL Relapse Despite...
City of Hope Medical Center’s Alex Herrera, MD, leads a Phase II clinical trial assessing the efficacy and safety of ADCT-301 (camidanlumab tesirine) in patients with relapsed or refractory Hodgkin lymphoma (HL). Sponsored by Swiss emerging biotech ADC Therapeutics...
Researchers at Rutgers Cancer Institute are looking at biomarkers in pediatric acute lymphoblastic leukemia patients to determine how to prevent neurocognitive impairment from standard treatment. Cancer treatments can cause permanent deterioration of brain functions...
